[1]
|
Y. W. Kim, S. M. Bae, G. Battogtokh, H. J. Bang and W. S. Ahn, “Synergistic Anti-Tumor Effects of Combination of Photodynamic Therapy and Arsenic Compound in Cervical Cancer Cells: In Vivo and in Vitro Studies,” PLos One, Vol. 7, No. 6, 2012, p. e38583. doi:/10.1371/journal.pone.0038583
|
[2]
|
P. Soergel, G. F. Dahl, M. Onsrud and P. Hillemanns, “Photodynamic Therapy of Cervical Intraepithelial Neoplasia 1-3 and HPV Infection with Methylaminolevulinate and Hexaminolevulinate-A Double-Blind, Dose-Finding Study,” Lasers in Surgery and Medicine, Vol. 44, No. 6, 2012, pp. 468-474. doi:/10.1002/lsm.22041
|
[3]
|
R. P. Johnson, C. W. Chung, Y. I. Jeong, D. H. Kang, H. Suh and I. Kim, “Poly (L-Histidine)-Tagged 5-Aminolevulinic Acid Prodrugs: New Photosensitizing Precursors of Protoporphyrin IX for Photodynamic Colon Cancer Therapy,” International Journal of Nanomedicine, Vol. 7, 2012, pp. 2497-2512.
|
[4]
|
M. E. Ortner, K. Caca, F. Berr, J. Liebetruth, U. Mansmann, D. Huster, W. Voderholzer, G. Schachschal, J. M?ssner and H. Lochs, “Successful Photodynamic Therapy for Nonresectable Cholangiocarcinoma: A Randomized Prospective Study,” Gastroenterology, Vol. 125, No. 5, 2003, pp. 1355-1363. doi:/10.1016/j.gastro.2003.07.015
|
[5]
|
J. T. Lau, P. C. Lo, W. P. Fong and D. K. Ng, “A Zinc(II) Phthalocyanine Conjugated with an Oxaliplatin Derivative for Dual Chemo- and Photodynamic Therapy,” Journal of Medicinal Chemistry, Vol. 55, No. 11, 2012, pp. 5446-5454. doi:/10.1021/jm300398q
|
[6]
|
C. B. Simone, J. S. Friedberg, E. Glatstein, J. P. Stevenson, D. H. Sterman, S. M. Hahn and K. A. Cengel, “Photodynamic Therapy for the Treatment of Non-Small Cell Lung Cancer,” Journal of Thoracic Disease, Vol. 4, No. 1, 2012, pp. 63-75.
|
[7]
|
M. L. Davila, “Photodynamic Therapy,” Gastrointestinal Endoscopy Clinics of North America, Vol. 21, No. 1, 2011, pp. 67-79. doi:/10.1016/j.giec.2010.09.002
|
[8]
|
J. M. Houle, N. Clervoix, S. Bain and J. Spénard, “Lack of Effect of Sex and Disease State on the Pharmacokinetics of Porfimer Sodium,” Clinical Pharmacokinetics, Vol. 45, No. 9, 2006, pp. 923-930.doi:/10.2165/00003088-200645090-00004
|
[9]
|
P. Baas, I. van Mansom, H. van Tinteren, F. A. Stewart and N. van Zandwijk, “Effect of N-Acetylcysteine on Photofrin-Induced Skin Photosensitivity in Patients,” Lasers in Surgery and Medicine, Vol. 16, No. 4, 1995, pp. 359-367. doi:/10.1002/lsm.1900160407
|
[10]
|
T. A. Katsumi, K. Aizawa, Y. Kuroiwa, K. Saito, Y. Kurata, Y. Ii, T. Okunaka, C. Konaka and H. Kato, “Photodynamic Therapy with a Diode Laser for Implanted Fibrosarcoma in Mice Employing Mono-L-As-partyl Chlorin E6,” Photochemistry and Photobiology, Vol. 64, No. 4, 1996, pp. 671-675. doi:/10.1111/j.1751-1097.1996.tb03122.x
|
[11]
|
D. Kessel, “Pharmacokinetics of N-Aspartyl Chlorin E6 in Cancer Patients,” Journal of Photochemistry and Photobiology B: Biology, Vol. 39, 1997, pp. 81-83. doi:/10.1016/S1011-1344(96)00009-7
|
[12]
|
X.-M. Hu, T. Hirano and K. Oka, “Arsenic Trioxide Induces Apoptosis Equally to T Lymphoblastoid Leukemia MOLT-4 Cells and P-gp Expressing Daunorubicin-Resistant MOLT-4 Cells,” Cancer Chemotherapy and Pharmacology, Vol. 51, No. 2, 2003, pp. 119-126. doi:/10.1007/s00280-003-0629-5
|
[13]
|
K. Kasuya, M. Shimazu, M. Suzuki, Y. Kuroiwa, J. Usuda, T. Itoi, A. Tsuchida and T. Aoki, “Novel Photodynamic Therapy against Biliary Tract Carcinoma Using Mono-L-Aspartyl Chlorine E6: Basic Evaluationfor Its Feasibility and Efficacy,” Journal of Hepato-Biliary-Pancreatic Surgery, Vol. 17, No. 3, 2010, pp. 313-321.doi:/10.1007/s00534-009-0246-8
|
[14]
|
Z.-L. Liu, T. Hirano, S. Tanaka, K. Onda and K. Oka, “Persistent Reversal of P-Glycoprotein-Mediated Daunorubicin Resistance by Tetrandrine in Multidrug-Resistant Human T Lymphoblastoid Leukemia MOLT-4 Cells,” Journal of Pharmacy and Pharmacology, Vol. 55, No. 11, 2003, pp. 1531-1537. doi:/10.1211/0022357022115
|
[15]
|
J. Usuda, S. Ichinose, T. Ishizumi, H. Hayashi, K. Ohtani, S. Maehara, S. Ono, H. Honda, N. Kajiwara, O. Uchida, H. Tsutsui, T. Ohira, H. Kato and N. Ikeda, “Outcome of Photodynamic Therapy Using NPE6 for Bronchogenic Carcinomas in Central Airways >1.0 cm in Diameter,” Clinical Cancer Research, Vol. 16, No. 7, 2010, pp. 2198-2204. doi:/10.1158/1078-0432.CCR-09-2520
|
[16]
|
J. Usuda, S. Ichinose, T. Ishizumi, H. Hayashi, K. Ohtani, S. Maehara, S. Ono, H. Honda, N. Kajiwara, O. Uchida, H. Tsutsui, T. Ohira, H. Kato and N. Ikeda, “Breast Cancer Resistant Protein (BCRP) is a Molecular Determinant of the Outcome of Photodynamic Therapy (PDT) for Centrally Located Early Lung Cancer,” Lung Cancer, Vol. 67, No. 2, 2010, pp. 198-204. doi:/10.1016/j.lungcan.2009.04.002
|